Redeye provides a brief initial take on Ultimovacs reporting more granular NIPU data. We positively view more mature data indicating better median overall survival and objective response rate for the treatment group (mOS c15.4 months, HR = 0.73, ORR c31%) versus controls (c11.1 months, c16%). As expected, PFS data are mixed, with central review showing no benefit (HR = 1.01), while local review indicates a benefit for the treatment group (HR = 0.60). Overall, we expect to raise our LoA for UV1 in mesothelioma and increase our valuation moderately. We expect the share to react positively. We will return with a more elaborate take on the readout early next week following release of the complete data set and the webcast with NIPU’s principal investigator.